ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,235.00
-0.32%
S&P ASX All Technology
3,849.60
-0.26%
Brent Oil
74.11
0.66%
US Dollar vs AUD
1.60557
-0.07%
Bitcoin
94,276.26
0.82%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. NEO

  6. Eli Lilly and Company (LLY) Share Price

Eli Lilly and Company

Eli Lilly and Company (LLY)

Eli Lilly and Co
Lilly Eli and Co
28.88
-0.32
( -1.10% )
Updated: 05:39:55
Realtime Data

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
28.88
Bid
28.85
Offer
28.89
Volume
18,644
28.72 Day's Range 28.95
0.00 52 Week Range 0.00
Previous Close
29.20
Open
28.92
Last Trade
200
@
28.88
Last Trade Time
05:39:26
Average Volume (3m)
-
Financial Volume
-
VWAP
-

Ask ADVFN Intelligence (AI)

LLY Latest News

More News

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity

FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity PR Newswire INDIANAPOLIS, Dec. 20, 2024...

21 December 2024
PR Newswire (US)

Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease

Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease PR Newswire INDIANAPOLIS, Dec. 17, 2024 China is the fourth major market where...

18 December 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

18 December 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

18 December 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

18 December 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

18 December 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

18 December 2024
Edgar (US Regulatory)

Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt

Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt PR Newswire INDIANAPOLIS and CAIRO, Dec. 17, 2024 This milestone stems from the companies...

17 December 2024
PR Newswire (US)

Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease

Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease PR Newswire INDIANAPOLIS, Dec. 13, 2024 The Phase...

14 December 2024
PR Newswire (US)

Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer

Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast...

12 December 2024
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

LLY - Frequently Asked Questions (FAQ)

What is the current Eli Lilly share price?
The current share price of Eli Lilly is $ 28.88
What is the 1 year trading range for Eli Lilly share price?
Eli Lilly has traded in the range of $ 0.00 to $ 0.00 during the past year

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BTQBTQ Technologies Corp
$ 4.37
(19.40%)
997.05k
VERSVerses AI Inc
$ 1.46
(18.70%)
1.51M
INXDINX Digital Company Inc
$ 0.09
(5.88%)
127k
HOLDImmutable Holdings Inc
$ 0.105
(5.00%)
17.76k
MOLYGreenland Resources Inc
$ 0.85
(2.41%)
40.25k
IFSSInterfield Global Software Inc
$ 0.02
(-42.86%)
6.22k
FHFilament Health Corp
$ 0.03
(-14.29%)
3k
CDMNCanadian Manganese Company Inc
$ 0.035
(-12.50%)
246.49k
GRAMGold Flora Corporation
$ 0.04
(-11.11%)
39.42k
NETZCarbon Streaming Corporation WTS B
$ 0.49
(-10.91%)
41.65k
VERSVerses AI Inc
$ 1.46
(18.70%)
1.51M
CBSTCannabist Company Holdings Inc
$ 0.075
(0.00%)
1.23M
BTQBTQ Technologies Corp
$ 4.37
(19.40%)
997.05k
DEFIValour Inc
$ 3.87
(-5.61%)
568.96k
CDMNCanadian Manganese Company Inc
$ 0.035
(-12.50%)
246.49k

Discussion

View Full Feed
fung_derf fung_derf 5 minutes ago
Other AI bots.....or a few special technicians......so only 92% of the work force ineffective.
AI
delerious1 delerious1 5 minutes ago
What's the supersack sitting on at the back....is that where it is emptied into the Mill??
NBRI
SniffinPennies SniffinPennies 5 minutes ago
End of Year tax sale almost over. Sellers now haven't been in the OTC very long to know the New Year trading pattern
CGAC
stocktowatch stocktowatch 5 minutes ago
$IVDN today issues the following letter to shareholders from new CEO Joseph A. Riccelli. This letter covers the Company's fiscal third quarter financial results and forward-looking projections, as well as a discussion of significant events in 2024 and plans for the future.


IVDN
amelia43 amelia43 5 minutes ago
Are we scooping up cheapies still?
FNMA
sab63090 sab63090 5 minutes ago
Hoskuld:

Yes, thanks!

I think your experience is extremely valuable and the recent price push UP signals that things have indeed changed!
AVXL
tw0122 tw0122 6 minutes ago
.73
MGOL
RIGATONI RIGATONI 6 minutes ago
.41 nice volume ~Rig
DimesForShares DimesForShares 6 minutes ago
I found myself in almost complete agreement with this post.  I wouldn't call 2024 'awesome' but I will go with 'very good.'  During this past year, KBLB learned what was needed to move silk from the laboratory to commercial production.  Thompson still has the challenge of sustaining production at th
KBLB
luckydude777 luckydude777 6 minutes ago
One thing to observe about ASST is that the company knows how to get the share price up above $1.00 for over 10 days to keep it from receiving one of those irritating Nasdaq price compliant notices.
ASST
LowFloatLopes LowFloatLopes 6 minutes ago
This will be a fun ride up in 2025 if crypto has a good year 
CYFRF
Involuntary-Recluse Involuntary-Recluse 6 minutes ago
My example of fraud is something like Bre-X, where you walk by the tailings, drop your gold ring on top, and issue PR's stating visible gold, hence the stock price hitting $200.

Cases like ASKH, are simple incompetence/negligence and stupidity as no one makes any $$ form this, with th
ASKH
McTank630 McTank630 6 minutes ago
Dear management,

Would love to hear a word from you! No PR announcement, just a real and raw interaction / update live on camera!

Kind regards,
Patient supporters
NWBO
powerbattles powerbattles 6 minutes ago
Share Structure
Market Cap Market Cap
642,022 - 12/27/2024
Authorized Shares
4,000,000,000 - 12/13/2024
Outstanding Shares 1,167,313,456 - 12/13/2024
Restricted 500,847,878 - 12/13/2024
Unrestricted 666,465,578 - 12/13/2024
Held at DTC 534,815,
AFFU
tw0122 tw0122 7 minutes ago
Little action

MGOL
Slim6 Slim6 7 minutes ago
QUBT is going to lose another $300 million during the next year. This is getting worse. The tangible book value has already gone into negative. Dilution continues as shareholders are duped further. Beware. The company is teetering on bankruptcy.
QUBT
Shareing is winning Shareing is winning 7 minutes ago
GET YOUR BUY;S IN AT .021 OR BE LEFT BEHIND LITTERALLY!
TORVF
RIGATONI RIGATONI 7 minutes ago
.989 new high ~Rig
LowFloatLopes LowFloatLopes 7 minutes ago
Finally back on the run .. it's been stuck in a sideways pattern last few weeks 
CYFRF
tw0122 tw0122 8 minutes ago
BLBX might be it for now $4.10
BLBX
maddyandboomer maddyandboomer 8 minutes ago
The ask is 35 times the size of bid at trip 8....oh sorry - that is a bad thing
AXXA
Whalatane Whalatane 8 minutes ago
Health providers typically renegotiate drug supply contracts annually, though practices can vary. Here's a breakdown of common renegotiation frequencies:
Annual Renegotiation
Most healthcare organizations and physicians review and renegotiate their major payer contracts at least once a
UNCY
Golden Cross Golden Cross 8 minutes ago
$ILLR Conor McGregor Wants To Convert #BKFC Into A Global Phenomenon. BKFC President David Feldman says
Conor McGregor has helped BKFC grow massively.
https://www.essentiallysports.com/ufc-mma-news-bkfc-president-says-conor-mcgregor-has-ten-folded-bkfc-metrics/

@triller
ILLR
Monksdream Monksdream 8 minutes ago
WATT, quite a gap to fill
https://investorshub.advfn.com/uimage/uploads/2024/12/30/arbaoIMG_4343.gif

Energous Corp. engages in the development of wireless charging technology. It focuses on the product, WattUp, a wireless power technology consisting of proprietary semiconductor
i_like_bb_stock i_like_bb_stock 8 minutes ago
TNON volume increasing catalyst upcoming "Successfully completed initial clinical cases (alpha) of Tenon's new Catamaran SE SI Joint Fusion System.

National introduction of Catamaran SE is expected in early 2025."
TNON

Your Recent History

NEO
LLY
Eli Lilly
BIT
UC3QNG
Unicredit Bank
FTSE
UB3020
FTSE 350 Construction & ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads